Pharmaceutical

SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform

MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel,…

1 year ago

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end…

1 year ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma,…

1 year ago

SteraMist Welcomes Sterile Grow as U.S. Distributor for Food Safety and Cannabis

-Partnership Expands TOMI’s Market in Food, Agriculture, and Cannabis Industries -FREDERICK, Md., Nov. 27, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental…

1 year ago

Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010

Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical…

1 year ago

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today…

1 year ago

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate…

1 year ago

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week…

1 year ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50,…

1 year ago